Frontlight ResearchEarly access
CompletedNo phase
Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System
Key facts
- Who runs it
- Cepheid
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 1,012 people enrolled
- Started
- 6 Feb 2024
- Ended
- 6 Jun 2024
- Type of study
- Observational
- Treatments tested
- Xpert HCV
- Record updated
- 19 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participant was ≥18 years old
- Participant was not on treatment at time of enrollment based on review of medical records or self-reported
- Participant had signs and symptoms and/or is considered at-risk of HCV infection
Who cannot take part
- Clinician assessed that the participant was not suitable for inclusion
Where in United States
- University of KentuckyLexington, United States
About the trial
What the trial wants to find out
A multi-site prospective, all comers study that was conducted at geographically diverse locations in the United States.
The group in the trial
- Capillary whole blood
Capillary whole blood from individuals with signs and symptoms and/or at-risk of HCV infection
Treatment: Xpert HCV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Evaluation of the Xpert® HCV Test on the GeneXpert® Xpress System
- Publications
- Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026
- Record updated
- 19 July 2024